A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

Status:
Withdrawn

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the effect of GS-1101 on the onset, magnitude, and duration of tumor control

Phase 2

Gilead Sciences

Idelalisib